Xeris Biopharma (XERS): Volume dana dhuwit perusahaan

Logo grafis xerispharma.com (XERS)

Xeris Biopharma (XERS) is developing a highly scalable finished-dose injection manufacturing model that ensures high profitability following the R&D phase. The volume of operating cash on this chart demonstrates current liquidity, while 0.13 captures the current state of the parameter. Business resilience is bolstered by the implementation of ESG standards into technical processes and the licensing of the platform to diversify risks within the endocrine drug niche.

Xeris Biopharma Holdings, Inc. - Dhuwit awis lan setara dhuwit awis perusahaan XERS (periode 04.07.2022 - 21.11.2026)

Rincian metrik keuangan lan pasar Xeris Biopharma Holdings (XERS)

- nilai saham lan prakiraan konsensus rega:
Analisis dhasar perusahaan:XERS xerispharma.com
Produk mawa merek xerispharma.com

This indicator aggregates liquid assets from the balance sheet, capturing the absolute volume of available funds to ensure operational stability without external borrowing. By analyzing the cash on hand via GURU.Markets, an investor assesses the ability of Xeris Biopharma (XERS) to fund the development of injectable drugs and the commercialization of pen injectors, where a sufficient reserve minimizes default risks amid sales volatility.